Richard Sulsky

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Masato Furuhashi, Gürol Tuncman, Cem Z. Görgün et al. · Nature · 2007 · 724 citations · Full text

Fatty-acid-binding Protein Ap2, Metabolic Syndrome, Biochemistry +7

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 268 citations

Hyperlipidemia, Whhl Rabbits, Metabolic Syndrome +17

Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)

Richard Sulsky, David R. Magnin, Yanting Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 150 citations · Full text

Lipid Synthesis, Biochemistry, Natural Sciences +6

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Glycobiology, Methanoprolinenitrile-containing Dipeptide Mimetics, Pharmacotherapy +19

A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors

Jeffrey A. Robl, Richard Sulsky, Chong‐Qing Sun et al. · Journal of Medicinal Chemistry · 2001 · 61 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Novel Series +13